BioLineRx Presents Data From Successful Phase I Trial for BL-1020
in Schizophrenia at American Psychiatric Association Conference
SAN DIEGO--(BUSINESS WIRE)--May 22, 2007 -
BioLineRx Ltd.(TASE:BLRX), Israel's leading drug development company, reportedtoday data from its Phase I trial of BL-1020, the first GABAenhanced antipsychotic clinical candidate for the treatment ofschizophrenia. The trial demonstrated that the compound was welltolerated and demonstrated biochemical evidence of dopamineblockade which is indicativ...
BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming
Clinical Conferences
JERUSALEM--(BUSINESS WIRE)--May 17, 2007 -
BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development company, announced todaythat abstracts containing data from its successfully completedphase I clinical trails of BL-1020, first in class GABA-enhancedantipsychotic for the treatment of schizophrenia, have beenaccepted for poster presentations at three leading scientificconferences. The d...
BioLineRx Presents Data on BL-1040 at Cardiovascular
Revascularization Therapies Conference Demonstrating Potential to
Reduce Deterioration of Infarcted Heart Tissue and Maintain
Functionality
JERUSALEM--(BUSINESS WIRE)--Mar 7, 2007 -
BioLineRx Ltd.(TASE:BLRX), Israel's leading drug development company, reportedtoday pre-clinical data from trials of BL-1040 demonstrating thatBL-1040 is effective in preventing deterioration of the myocardiumafter a myocardial infarction (MI), thereby reducing left ventricledilatation and eventual heart failure in a pig model. ProfessorJonathan Leo...